Stock Market & Financial Investment News

News Breaks November 23, 2012 06:42 EDT VVUS, AMRN Stocks with implied volatility movement; VVUS ARMN Stocks with implied volatility movement; VIVUS (VVUS), Amarin (AMRN) according to iVolatility. News For VVUS;AMRN From The Last 14 Days Check below for free stories on VVUS;AMRN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 11:56 EDT AMRN Options with decreasing implied volatility: WCRX NTI PXP AMRN BBY 06:07 EDT AMRN Amarin announces patent allowance related to combination of Vascepa, Statin Amarin announced that the United States Patent and Trademark Office has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/417,899 titled "Pharmaceutical Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using the Same." This application includes claims intended to protect the Vascepa indication approved by the FDA based on Amarin's MARINE clinical trial results specifically those results seen in patients on statin therapy. The claims in this allowed application cover a method to reduce triglycerides in subjects having a triglyceride level of 500mg/dl to 1500mg/dl who are also receiving statin therapy using an amount of Vascepa effective to reduce triglycerides without substantially increasing low density lipoprotein cholesterol. May 21, 2013 11:41 EDT AMRN Options with decreasing implied volatility: SGMO WCRX NTI TSLA AMRN May 17, 2013 14:12 EDT AMRN Amarin shares slip after FDA updates Orange Book Subscribe for More Information May 15, 2013 11:04 EDT AMRN Amarin management to meet with Lazard Capital Meeting to be held in the Mid-Atlantic area on May 16 hosted by Lazard Capital. May 14, 2013 10:01 EDT VVUS On The Fly: Analyst Downgrade Summary Today's noteworthy downgrades include: AVG Technologies (AVG) downgraded to Neutral from Buy at Goldman... Cigna (CI) downgraded to Hold from Buy at Jefferies... Cree (CREE) downgraded to Neutral from Buy at Sterne Agee... Melco Crown (MPEL) downgraded to Neutral from Buy at UBS... SolarCity (SCTY) downgraded to Neutral from Buy at Roth Capital... KB Home (KBH) downgraded to Market Perform from Outperform at Raymond James... Ryland Group (RYL) downgraded to Underperform from Market Perform at Raymond James... Alere (ALR) downgraded to Hold from Buy at Craig-Hallum... Evolution Petroleum (EPM) downgraded to Hold from Buy at MLV Equity... Oil States (OIS) downgraded to Hold from Buy at BB&T... VIVUS (VVUS) downgraded to Neutral from Buy at Lazard Capital. 07:33 EDT VVUS VIVUS downgraded to Neutral from Buy at Lazard Capital Subscribe for More Information May 13, 2013 12:52 EDT AMRN Amarin strength attributed to MassHealth drug list addition Subscribe for More Information 07:41 EDT VVUS VIVUS mails letter to stockholders providing business update Subscribe for More Information May 10, 2013 09:23 EDT AMRN Amarin continues to make progress with payors, says Leerink Leerink reiterates an Outperform rating on shares of Amarin following the company's Q1 results. The firm believes Amarin continues to make good progress with payors and that Vascepa script trends are tracking well. May 9, 2013 16:18 EDT AMRN Amarin reports Q1 EPS (41c), consensus (39c) Reports Q1 revenue $2.34M, consensus $5.2M. Amarin said its direct sales force, consisting of approximately 275 sales professionals, made sales calls to clinicians for two months in Q1. Amarin reports that, since launch, access to clinicians has been good, and that it has yet to hear any significant negative reaction to the efficacy or safety profile of Vascepa. Amarin said it continues to make significant progress in its effort to expand patent protection for Vascepa and now has 22 patents issued or allowed in the United States with over 30 additional U.S. patent applications being prosecuted. 13:15 EDT AMRN Amarin, Omthera drop following fatty acids study in journal Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.